雲想科技(02131.HK)超額配股權獲部分行使 穩定價格期結束
格隆匯1月10日丨雲想科技(02131.HK)公佈,於2021年1月9日,獨家全球協調人(代表國際包銷商)已就合共2832萬股股份(相當於根據全球發售於任何超額配股權獲行使前初步可供認購的發售股份總數約14.16%)部分行使超額配股權,以便向超額配股權授予人戴氏特殊目的實體及巨漳資產歸還根據借股協議借入的部分股份,該等股份乃用於補足國際發售的超額分配。超額配股權授予人將按每股發售股份6.98港元出售超額配發股份。
與全球發售有關的穩定價格期已於2021年1月9日(即截至遞交香港公開發售申請日期後第30日)結束。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.